Bhave Prashant D, Lu Xin, Girotra Saket, Kamel Hooman, Vaughan Sarrazin Mary S
University of Iowa Hospitals and Clinics, Iowa City, Iowa.
University of Iowa Hospitals and Clinics, Iowa City, Iowa.
Heart Rhythm. 2015 Jul;12(7):1406-12. doi: 10.1016/j.hrthm.2015.03.031. Epub 2015 Mar 23.
Atrial fibrillation (AF) is associated with an increased risk of stroke and death. Uniform utilization of appropriate therapies for AF may help reduce those risks.
We sought to determine whether significant race and sex differences exist in the treatment of newly diagnosed AF in Medicare beneficiaries.
We used administrative encounter data for Medicare beneficiaries to identify patients with newly diagnosed AF during 2010-2011. Services received after initial AF diagnosis were cataloged, including visits with a cardiologist or electrophysiologist, catheter ablation procedures, and use of oral anticoagulants, rate control agents, and antiarrhythmic drugs.
Overall, 517,941 patients met study criteria, of whom 452,986 (87%) were white, 36,425 (7%) black, and 28,530 (6%) Hispanic. Male patients comprised 209,788 (41%) of the cohort. In multivariate analysis, there were statistically significant differences in the use of AF-related services by both race and sex, with white patients and male patients receiving the most care. The most notable disparities were for catheter ablation (Hispanic vs white: adjusted hazard ratio [AHR] 0.70; 95% confidence interval [CI] 0.63-0.79; P < .001; female vs male: AHR 0.65; 95% CI 0.63-0.68; P < .001) and receipt of oral anticoagulation (black vs white: AHR 0.94; 95% CI 0.92-0.95; P < .001; Hispanic vs white: AHR 0.94; 95% CI 0.93-0.97; P < .001; female vs male: AHR 0.93; 95% CI 0.93-0.94; P < .001).
Race and sex appear to have a significant effect on the health care provided to this cohort of Medicare beneficiaries diagnosed with AF. Possible explanations include racial differences in access, patient preferences, treatment bias, and unmeasured clinical characteristics.
心房颤动(AF)与中风和死亡风险增加相关。对AF采用统一的适当治疗方法可能有助于降低这些风险。
我们试图确定医疗保险受益人中新诊断AF的治疗是否存在显著的种族和性别差异。
我们使用医疗保险受益人的行政就诊数据来识别2010 - 2011年期间新诊断AF的患者。记录首次AF诊断后接受的服务,包括与心脏病专家或电生理学家的就诊、导管消融手术以及口服抗凝剂、心率控制药物和抗心律失常药物的使用情况。
总体而言,517,941名患者符合研究标准,其中452,986名(87%)为白人,36,425名(7%)为黑人,28,530名(6%)为西班牙裔。男性患者占队列的209,788名(41%)。在多变量分析中,种族和性别在AF相关服务的使用上均存在统计学显著差异,白人患者和男性患者接受的治疗最多。最显著的差异在于导管消融(西班牙裔与白人:调整后风险比[AHR] 0.70;95%置信区间[CI] 0.63 - 0.79;P <.001;女性与男性:AHR 0.65;95% CI 0.63 - 0.68;P <.001)以及口服抗凝治疗的接受情况(黑人与白人:AHR 0.94;95% CI 0.92 - 0.95;P <.001;西班牙裔与白人:AHR 0.94;95% CI 0.93 - 0.97;P <.001;女性与男性:AHR 0.93;95% CI 0.93 - 0.94;P <.001)。
种族和性别似乎对这群被诊断为AF的医疗保险受益人所接受的医疗保健有显著影响。可能的解释包括就医机会的种族差异、患者偏好、治疗偏见以及未测量的临床特征。